Litfulo (ritlecitinib) for vitiligo: investigational evidence and risks

Litfulo is the brand name for ritlecitinib, an oral Pfizer medicine that inhibits JAK3 and the TEC family of kinases. Those immune-signaling effects supply a rationale for study in vitiligo, but a mechanism cannot show that the medicine will help a particular person.⌁ Evidence⌁ Evidence

Litfulo is authorized in the United States, European Union, and Great Britain for severe alopecia areata in defined populations, not for vitiligo. Pfizer has reported positive phase 3 vitiligo topline results and plans adult regulatory filings, but a planned filing is not an application decision or a vitiligo indication.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence

A peer-reviewed randomized phase 2 study treated 364 adults with active nonsegmental vitiligo. At week 24, four of five active arms had statistically significant differences from placebo, with three distinct mean facial-score improvements: 21.2% in two arms, 18.5%, and 14.6%. Placebo worsened by 2.1%, and people with stable-only vitiligo were excluded. A sponsor-linked analysis reported group-level facial-score changes in Fitzpatrick types I–III and IV–VI. That does not establish the same response for every skin tone or person. Pfizer later said the 607-person TRANQUILLO and 1,567-person TRANQUILLO 2 studies met facial and total-body endpoints. The release did not provide response percentages or full result tables, and the current TRANQUILLO 2 registry now lists 1,571 enrolled, so the public enrollment counts are not identical.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence

The current US Litfulo label, written for severe alopecia areata, carries boxed warnings for serious infections, mortality, malignancy, major cardiovascular events, and thrombosis. It lists known hypersensitivity to ritlecitinib or an ingredient as a contraindication. It also describes infection and tuberculosis screening, blood-count monitoring, vaccination, interaction, pregnancy, breastfeeding, liver-related precautions, and a June 2026 warning about hypoglycemia in patients with diabetes. Parts of the boxed-warning context come from a large postmarketing study of another JAK inhibitor. That study was in people age 50 or older with rheumatoid arthritis and at least one cardiovascular risk factor. Some events occurred in Litfulo’s alopecia areata safety database. These boundaries matter, but they are not vitiligo-specific event rates or a personal risk calculation.⌁ Evidence⌁ Evidence

Current commercial access is for an approved alopecia indication. Vitiligo access would therefore be research or off-label care unless a regulator later authorizes it, and a prescription would not guarantee coverage. Specialist visits, screening, laboratory work, interaction review, follow-up, and payer decisions add burden.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence

A phase 2 extension compared 43 people in an add-on narrowband-UVB group with 187 receiving ritlecitinib alone. At extension week 24, 44.4% versus 27.4% reached F-VASI75 when missing values used last observation carried forward; that difference was not statistically significant. In the observed-case analysis, 60.9% versus 29.2% reached F-VASI75 and the difference was statistically significant. The add-on group had a stopping rule that the other group did not. These analysis-dependent results cannot establish combination superiority or define a routine sequence.⌁ Evidence

Full peer-reviewed phase 3 response and safety tables, durability, phase 3 subgroup findings, and reliable outcomes for hands, feet, or other individual sites remain unavailable in the reviewed sources. Patient stories can identify burden and priorities, but they cannot establish typical benefit, safety, approval, or who should take a systemic medicine.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence